Therapeutic peptides and proteins are usually delivered via parenteral routes, such as intravenous, subcutaneous, and intramuscular injections. These are high-cost delivery methods with poor patient compliance. Delivery of these proteins via the pulmonary route represents an attractive, non-invasive alternative.

Pulmonary delivery of proteins or peptides, either for local or systemic activity, requires the control of specific particle and powder properties. RightSize Particle technology meets this challenge by facilitating the design of particles for optimal delivery to the lungs.

Peptides

Mild operating conditions mean that RightSize Particle technology is ideally suited to processing biomolecules, including proteins and peptides. Excipients are easily incorporated into the process where necessary, for example, to improve stabilization.

Biopharmaceuticals are produced with controlled size, good flowability and controlled amounts of residual water.

• Increase delivery options
• Simplify drug formulation
• Increase shelf life
• Simplify handling

Insulin produced with RightSize Particle technology.